Business Context and Reporting Period
Company: Alzamend Neuro, Inc. (ALZN)
Filing Type: Form 8-K (Current Report)
Date of Report: August 3, 2026
Reporting Period: Events occurring on July 31, 2026 (Execution Date) and July 20, 2026 (Nasdaq Notice).
The Company entered into a material definitive agreement for a convertible preferred stock financing and notified Nasdaq of non-compliance with the majority independent board standard following the passing of an independent director.
Key Financial Metrics and Capital Structure
Financing Details:
- Instrument: Series D Convertible Preferred Stock.
- Total Facility: Up to $25 million in aggregate.
- Initial Closing: $7.5 million raised on July 31, 2026 (7,500 shares).
- Committed Second Tranche: $2.5 million.
- Optional Tranches: Up to $15 million available in subsequent closings.
- Stated Value: $1,050 per share.
- Origination Fee: 2% of the purchase price at each closing.
Conversion Terms:
- Conversion Price: Greater of $0.2668 (Floor Price) or 80% of the lowest closing bid price of Common Stock during the five trading days prior to conversion, capped at $2.00 (Maximum Price).
- Dividends: None accrued.
- Liquidation Preference: Holders receive Stated Value before common stockholders.
Liquidity and Debt: The filing does not provide specific cash balance, total debt, or operating cash flow figures. The financing is intended to provide capital, with the initial tranche adding $7.5 million in cash proceeds (net of fees).
Material Changes and Corporate Governance
Board Composition Change:
- Event: Independent Director Lynne Fahey McGrath passed away on July 20, 2026.
- Impact: The Board now consists of six members, only three of whom are Independent Directors.
- Compliance Status: The Company is currently non-compliant with Nasdaq Listing Rule 5605(b)(1) (Majority Independent Board Standard).
Financing Structure Change:
- Issuance of a new class of equity (Series D) with significant anti-dilution protections, registration rights, and a right of first refusal for the Purchaser (an affiliate) on future financings for three years.
Outlook, Risks, and Management Commentary
Registration Rights and Penalties:
- The Company must file a registration statement for the conversion shares by the earlier of 5 days after the 2026 10-K filing or August 15, 2026.
- Penalty: If the registration statement is not filed or declared effective by the deadline, the Company must pay liquidated damages of 2% of the Stated Value of Preferred Shares held monthly, up to a maximum of 15%.
Stockholder Approval:
- The Company must seek stockholder approval for the issuance of conversion shares exceeding the 19.99% Nasdaq limit. A special meeting must occur within 75 days of the Execution Date.
Risks and Contingencies:
- Delisting Risk: The Company has a cure period to regain compliance with the independent board standard until the earlier of its next annual meeting or July 20, 2027 (or January 18, 2027, if the annual meeting is earlier). There is no assurance compliance will be achieved.
- Dilution: The conversion price includes a "floor" of $0.2668 but can adjust downward if the Company issues stock at a lower price, subject to the floor.
- Restrictive Covenants: The Company is restricted from entering into more favorable terms with other investors without extending those terms to the Purchaser.
Investor Verification Checklist
- Board Compliance: Verify the timeline and progress of the Company's efforts to appoint new independent directors to meet the Nasdaq cure deadline.
- Registration Filing: Confirm the filing date of the Registration Statement for the Series D conversion shares to avoid the 2% monthly penalty.
- Stockholder Meeting: Monitor the scheduling and outcome of the special stockholder meeting required to approve the issuance of shares exceeding the 19.99% limit.
- Subsequent Closings: Track whether the Company exercises the option to close the additional $17.5 million in tranches and the associated dilution impact.
- Financial Position: Review the most recent Form 10-K or 10-Q for current cash balances and burn rate, as this 8-K does not provide updated liquidity metrics.